International Conference on Clinical Trials in Diabetes Research ICCTDR | 26

About the event

*Latest advances in clinical trials and diabetes research. *Modern approaches to designing and conducting Type 1 and Type 2 diabetes clinical trials. *Clinical trial phases, study protocols, randomization, blinding, control groups, and comparator selection. *Selection of appropriate primary and secondary endpoints for diabetes trials, including HbA1c, glucose measures, time in range, and other metabolic outcomes. *Use of continuous glucose monitoring (CGM) and digital biomarkers in diabetes clinical research. *Strategies for evaluating the efficacy, safety, tolerability, and long-term benefits of emerging diabetes therapies. *Advances in clinical trials involving insulin, GLP-1–based therapies, glucose-lowering drugs, and other novel treatments. *Emerging research on immunotherapies, β-cell replacement, cellular therapies, and disease-modifying treatments for Type 1 diabetes. *Innovative adaptive, platform, and personalized clinical trial designs in diabetes research. *Assessment of cardiovascular, renal, metabolic, and other diabetes-related outcomes in clinical trials. *Approaches to monitoring and reporting adverse events, hypoglycemia, treatment complications, and patient safety. *Statistical principles including sample-size calculation, statistical power, interim analysis, and interpretation of trial results. *Good Clinical Practice (GCP), research ethics, participant protection, and data integrity in diabetes trials. *Regulatory and methodological considerations for developing and evaluating new antidiabetic drugs and biological products. *Use of patient-reported outcomes, quality-of-life measures, and real-world data to evaluate treatment effectiveness. *Strategies for translating clinical-trial findings into evidence-based diabetes care and clinical practice. *Current research findings, emerging technologies, and future directions in diabetes clinical trials and therapeutic development.